Posts

Release Testing Strategies for Cell and Gene Therapy Products

Image
As cell and gene therapies advance from clinical development to commercial manufacturing, ensuring consistent product quality has become a top priority. Unlike conventional pharmaceuticals, these products are composed of living cells or genetic material that are highly sensitive to manufacturing conditions. A comprehensive Release Testing strategy verifies that every batch meets predefined quality specifications before it reaches patients. When combined with robust in-process testing, release testing forms the foundation of quality assurance for Advanced Therapy Products (ATPs). In 2026, regulatory agencies continue to strengthen expectations for product characterization, analytical validation, and quality control. Manufacturers that implement well-designed release testing programs are better positioned to reduce batch failures, support regulatory submissions, and accelerate commercialization. What Is Release Testing? Release Testing is the final quality assessment performed after man...
Post a Comment
Read more

Why Flow Cytometry Immunophenotyping Matters in Cell Therapy

Image
Cell therapies are transforming the treatment of cancer, autoimmune disorders, and rare diseases, but their success depends on maintaining strict quality standards throughout development and manufacturing. Since these products consist of living cells, manufacturers must accurately identify, characterize, and monitor cell populations to ensure product safety, consistency, and efficacy. This is where flow cytometry immunophenotyping plays a vital role. As the cell and gene therapy industry expands in 2026, flow cytometry has become one of the most widely used analytical techniques for confirming cell identity, assessing purity, and supporting regulatory compliance. When integrated into Current Good Manufacturing Practice (cGMP) workflows, it helps manufacturers generate reliable analytical data that supports successful product development and commercialization. What Is Flow Cytometry Immunophenotyping? Flow cytometry immunophenotyping is an analytical technique that identifies and quant...
Post a Comment
Location: India
Read more

NK Cell Manufacturing in 2026: Challenges, Innovations and Commercial Opportunities

Image
Natural killer (NK) cell therapies are gaining significant attention in the cell and gene therapy industry. Their ability to recognize and eliminate tumor cells without prior sensitization has positioned them as a promising alternative to other cell-based immunotherapies. As clinical pipelines expand, NK cell manufacturing is becoming a major focus for biotechnology companies seeking scalable and cost-effective therapeutic platforms. However, moving NK cell therapies from research to commercialization presents several manufacturing and operational challenges. In 2026, the industry is increasingly focused on improving manufacturing efficiency, enabling allogeneic production, and developing scalable platforms that support commercial growth. Why NK Cell Therapies Are Gaining Momentum NK cells offer several advantages compared with other cell therapies: Lower risk of graft-versus-host disease (GvHD) Potential for off-the-shelf manufacturing Broad anti-tumor activity Compatibility with com...
Post a Comment
Location: Kowloon, Hong Kong
Read more

Flow Cytometry Immunophenotyping in Cell Therapy: A Practical Guide

Image
Cell therapy products are, quite literally, made of cells — which means proving what those cells actually are is one of the most fundamental steps in demonstrating product identity, purity, and safety. That's where flow cytometry immunophenotyping comes in. It's one of the most widely used analytical techniques in cell therapy development, and understanding how it works — and where it fits into your testing strategy — matters for anyone bringing a cell therapy product toward the clinic. What Is Flow Cytometry Immunophenotyping? Flow cytometry immunophenotyping is a technique used to identify and characterize cell populations based on the surface and intracellular markers they express. Cells are labeled with fluorescently tagged antibodies that bind to specific proteins — such as CD3, CD4, CD8, CD19, or CD56, depending on the therapy — and then passed single-file through a laser-based detection system. As each cell passes through, the instrument measures the fluorescence and ...
Post a Comment
Read more

Why Clinical Grade iPSC Manufacturing Is Critical for Future Cell Therapies

Image
The cell and gene therapy field is rapidly evolving, with induced pluripotent stem cells (iPSCs) emerging as a foundational technology for next-generation treatments. Unlike limited adult stem cells, iPSCs offer virtually unlimited expansion potential and the ability to differentiate into virtually any cell type, making them ideal for regenerative medicine, immuno-oncology, and rare disease therapies. However, translating this promise into safe, effective therapies requires stringent clinical grade iPSC manufacturing standards. As demand for scalable allogeneic cell therapies grows, robust iPSC manufacturing services are becoming essential for developers aiming to move from research to clinical and commercial success. The Unique Potential and Challenges of iPSC-Based Therapies iPSCs can be derived from adult cells and reprogrammed into a pluripotent state, then differentiated into specialized cells such as cardiomyocytes, neurons, beta cells, or immune cells. This versatility opens do...
Post a Comment
Read more

Rapid Mycoplasma Testing vs Traditional Methods: Which Is Better for ATMPs?

Image
Advanced Therapy Medicinal Products (ATMPs) are transforming modern healthcare through innovative treatments such as cell therapies, gene therapies, and tissue-engineered products. As these therapies move toward commercialization, maintaining strict quality and safety standards becomes increasingly important. One of the biggest concerns in ATMP manufacturing is microbial contamination, especially mycoplasma contamination, which can compromise product quality, patient safety, and regulatory compliance. Because of this risk, reliable mycoplasma detection and robust sterility testing strategies are essential throughout the manufacturing process. However, manufacturers often face a critical question: should they rely on traditional testing methods or adopt rapid mycoplasma testing technologies? Understanding the Risk of Mycoplasma Contamination Mycoplasmas are small bacteria that lack a cell wall, making them difficult to identify through standard microscopy. They can spread quickly in ce...
Post a Comment
Location: Kowloon, Hong Kong
Read more

How Clinical Trials Are Driving Innovation in Cell-Based Therapies

Image
The biotechnology industry is rapidly evolving as researchers and healthcare organizations continue developing innovative treatments for complex diseases. Among the most promising advancements are cell-based therapies, which are transforming modern medicine by offering targeted and regenerative treatment approaches. These therapies are creating new possibilities for conditions that previously had limited treatment options, including cancer, autoimmune disorders, and rare genetic diseases. One of the biggest drivers behind this progress is the growing number of Clinical Trials focused on advanced therapeutic solutions. Clinical studies play a critical role in evaluating safety, effectiveness, and manufacturing reliability before therapies become widely available to patients. As research expands globally, clinical trials continue accelerating innovation in modern healthcare. Understanding Cell-Based Therapies Cell-based therapies use living cells to repair, replace, or regenerate damage...
Post a Comment
Read more